STAT+: With new data on its KRAS-blocking lung cancer drug, Mirati expects to take on a rival Amgen treatment

As Mirati Therapeutics waits for the Food and Drug Administration to complete a review of its KRAS-targeting lung cancer drug later this year, final results from a clinical trial reported Thursday could both help and hinder the biotech’s efforts to stand apart from a rival Amgen treatment approved one year ago.

In its own clinical trial, the Mirati drug, called adagrasib, shrank tumors in 43% of patients with advanced lung cancer — a result that tops the 37% response rate from a study reported by Amgen for its drug, called Lumakras.

Continue to STAT+ to read the full story…

Leave a Reply